Can semaglutide show up on a drug test?

Picture the moment: you've been offered a workplace screen and you're mid-way through Wegovy

You pick up your phone and search because nobody warned you about this, and you don't want a surprise. It's a reasonable thing to worry about. The short, honest answer is that a standard five- or ten-panel urine screen has nothing in it that responds to semaglutide. Those panels target the metabolites of a defined list of controlled or misused substances (usually cannabis, cocaine, opiates, amphetamines, and benzodiazepines) and semaglutide's molecular structure doesn't cross any of those thresholds.

Semaglutide is a glucagon-like peptide-1 receptor agonist: a synthetic version of a gut hormone your body produces naturally. From a pharmacological classification standpoint it sits alongside medicines like insulin or other peptide therapies. None of those are on standard panels. If a test came back flagged because of semaglutide, the lab equipment would need to have been specifically programmed to find it. That almost never happens outside highly specialised clinical or research settings.

For more detail on how semaglutide works as a medicine, the semaglutide overview on this site covers the mechanism and licensed uses in plain language. If you're exploring branded formulations, you can also read about how Fitaro delivers semaglutide as a licensed treatment option. The NHS also publishes a patient-level guide covering what semaglutide is and how it affects the body at nhs.uk/medicines/semaglutide.

Could semaglutide affect a blood test result?

This is a slightly different question, and it's worth separating out. A drug-detection blood test (the kind used in legal, employment, or sporting contexts) works the same way as a urine panel: it screens for specific compound classes. Semaglutide won't register on those.

What semaglutide can do is change some routine clinical blood markers over time. It lowers HbA1c and fasting glucose in people with elevated levels, improves lipid profiles in some patients, and may affect liver enzyme readings. These are clinically meaningful changes that your GP would want to know about, they're not a sign something has gone wrong, but they can shift values that appear in a standard health check. If you're due a blood test for an unrelated reason while taking Wegovy, tell the ordering clinician. Not because it will cause a false positive on a drug screen, but because honest disclosure leads to accurate interpretation.

There's a fuller breakdown of what actually happens in blood results on the dedicated blood test page, which covers both the detection question and the clinical marker question separately.

Military and specialist screening: does the context change things?

Military drug testing programmes in the UK tend to use more comprehensive panels than standard workplace screens, and this is a question that comes up often enough that it deserves a direct answer. As of July 2026, semaglutide is not included on UK Armed Forces routine drug testing panels. The panels target substances with abuse or impairment potential; Wegovy has no psychoactive properties and is not a substance of misuse.

Where the military context does matter is disclosure. Serving personnel are typically required to inform their chain of command and their medical officer about any prescription medicine they're taking. Failing to disclose a prescription (not the medicine itself) is the issue that can create problems. If you're in the Armed Forces or a similar regulated employment context, talk to your medical officer before starting any new prescription treatment. The specific implications for military personnel are covered in more detail on the military drug test page.

Sports anti-doping is a separate framework entirely. The World Anti-Doping Agency (WADA) publishes a prohibited list updated annually; semaglutide does not appear on it. If you compete at a level where WADA rules apply, check the current list via your sport's governing body, that's the definitive source, not general guidance.

One practical thing to do regardless

Disclose your prescription. This applies whether you're doing a pre-employment screen, a DOT check, or a clinical blood draw. Semaglutide won't trigger a positive on any standard panel, but the person reading your results should know what medicines you're on. In a clinical context this is especially important: a prescriber interpreting your blood glucose or cholesterol results needs the full picture to do it accurately.

Wegovy is a prescription-only medicine in the UK. It's dispensed following a clinical assessment by a registered prescriber, not sold over the counter or through unregulated channels. If you're considering treatment for weight management, Wegovy's UK licensing, eligibility, and how the treatment works is a good place to start, and the cost context page covers what private treatment typically involves financially. Questions about whether treatment might be right for you are answered through a consultation, you can start a free one here. A real prescriber reviews it the same day; your notes don't sit in an automated queue.